EU Commission’s Draft Standardization Request

by | Nov 20, 2020 | EU, EU MDR, FDA, Medical Devices, Quality, Regulatory, Standardization, Standards

The EU MDR and the IVDR layout the performance and safety requirements for medical devices and In-vitro diagnostics respectively in the EU. According to Article 8 of the EU MDR and the IVDR, manufacturers that comply with the harmonized standards are presumed to conform to the requirements of the European regulations.1

In the past, based on several standardization mandates issued by the Commission, the European Committee for Standardization (CEN) and the European Committee for Electrotechnical Standardization (Cenelec) have drafted harmonized standards in support of MDD and IVDD. The EU Commission is now proposing the revision of these harmonized standards to take into account the requirements set out in Regulations (EU) 2017/745 and (EU) 2017/746 and help ensure a high level of public safety and to facilitate free movement of devices in the EU Union. 1

In the EU, standardization requests are subject to acceptance by the relevant European standardization organization. This standardization request includes a list of 151 existing standards to be revised and 28 new standards to be drafted to support the MDR 2017/745; as well as 45 existing standards to be revised and 3 new standards to be drafted to support the IVDR 2017/746.1

Some of the standards to be revised for medical devices include:1

  • EN ISO 10993-1:2018 Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process
  • EN ISO 13485:2016+AC:2018+prA1 Medical devices – Quality management systems – Requirements for regulatory purposes
  • EN ISO 14971:2019 Medical devices – Application of risk management to medical devices

And the ones that need to be newly drafted to support compliance with EU MDR include:1

  • Medical gloves for single use – Part 5: Extractable chemical residues (prEN 455-5)
  • Active implantable medical devices – Electromagnetic compatibility – EMC test protocols for implantable cardiac pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization devices (ISO 14117)
  • Medical electrical equipment – Part 2-83: Particular requirements for the basic safety and essential performance of home light therapy equipment (IEC 60601-2-83)

EU Commission believes that since these standards are technology-neutral and purely performance-based, it will ensure a healthy competition in the economy to get the product to market and indirectly reduce the cost of sale associated with these devices.1

It is important to understand the impact of these changes to your product. Call us today to understand how these changes may impact you. Give us a call at +1 248-987-4497 or email us at

1EU Commissions (Oct 2020) Possible future standardisation requests to the European standardisation organisations retrieved on 11/18/2020 from

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This